aducanumab

Home
Ligands
aducanumab

GtoPdb Ligand ID: 8325

Synonyms: aducanumab-avwa | Aduhelm® | BART | BIIB-037 | BIIB037

aducanumab is an approved drug (FDA (2021))

Comment: Aducanumab is a fully human IgG1-kappa monoclonal antibody directed against the amyloid beta (Aβ) found in the amyloid plaques in the brain tissue of patients with Alzheimer's disease (AD).
Peptide sequences and structural information about this antibody are available from its IMGT/mAb-DB record. A patent search reveals Biogen Idec's patent submission WO2014089500 [2].

References
1. Biogen. Q3 2019 Financial Results and Business Update. Accessed on 03/12/2019. Modified on 03/12/2019. investors.biogen.com, http://investors.biogen.com/static-files/40565136-b61f-4473-9e58-9be769bbac6c
2. Bussiere T, Weinreb PH, Engber T, Rhodes K, Arndt J, Qian F, Dunstan RW, Patel S. (2014) A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES. Patent number: WO2014089500. Assignee: Biogen Idec International Neuroscience Gmbh. Priority date: 07/12/2012. Publication date: 12/06/2014.
3. Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. (2021) Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther, 13 (1): 98. [PMID:33971962]
4. Howard R, Liu KY. (2020) Questions EMERGE as Biogen claims aducanumab turnaround. Nat Rev Neurol, 16 (2): 63-64. [PMID:31784690]
5. Liu KY, Schneider LS, Howard R. (2021) The need to show minimum clinically important differences in Alzheimer's disease trials. Lancet Psychiatry, 8 (11): 1013-1016. [PMID:34087114]
6. Schneider L. (2019) A resurrection of aducanumab for Alzheimer's disease. The Lancet Neurology, In Press, Corrected Proof. DOI: 10.1016/S1474-4422(19)30480-6
7. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y et al.. (2016) The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature, 537 (7618): 50-6. [PMID:27582220]

References

1. Biogen.
Q3 2019 Financial Results and Business Update.
Accessed on 03/12/2019. Modified on 03/12/2019. investors.biogen.com, http://investors.biogen.com/static-files/40565136-b61f-4473-9e58-9be769bbac6c

2. Bussiere T, Weinreb PH, Engber T, Rhodes K, Arndt J, Qian F, Dunstan RW, Patel S. (2014)
A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES.
Patent number: WO2014089500. Assignee: Biogen Idec International Neuroscience Gmbh. Priority date: 07/12/2012. Publication date: 12/06/2014.

3. Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. (2021)
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
Alzheimers Res Ther, 13 (1): 98. [PMID:33971962]

4. Howard R, Liu KY. (2020)
Questions EMERGE as Biogen claims aducanumab turnaround.
Nat Rev Neurol, 16 (2): 63-64. [PMID:31784690]

5. Liu KY, Schneider LS, Howard R. (2021)
The need to show minimum clinically important differences in Alzheimer's disease trials.
Lancet Psychiatry, 8 (11): 1013-1016. [PMID:34087114]

6. Schneider L. (2019)
A resurrection of aducanumab for Alzheimer's disease.
The Lancet Neurology, In Press, Corrected Proof. DOI: 10.1016/S1474-4422(19)30480-6

7. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y et al.. (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Nature, 537 (7618): 50-6. [PMID:27582220]